Search for: "District of Columbia v. W. Bell & Co., Inc."
Results 1 - 20
of 20
Sorted by Relevance
|
Sort by Date
2 Feb 2016, 12:46 pm
”415 F.3d at 1320–21 (citing and quoting Bell Atl.Network Servs., Inc. v. [read post]
30 Nov 2015, 1:25 pm
Backus Hospital, 864 A.2d 1, 18 (Conn. 2005) (rejecting lost chance doctrine altogether).District of Columbia: Grant v. [read post]
12 Feb 2009, 10:42 am
We've been keeping an eye on some interesting litigation in the District of Columbia, Iacangelo v. [read post]
19 Feb 2016, 11:57 am
March 26, 2014) (District of Columbia) (non-product liability). [read post]
12 Jan 2011, 2:00 am
App. 1993); Southwestern Bell Tel. [read post]
18 Jul 2014, 11:55 am
PLIVA, Inc., 720 F.3d 739, 744 (8th Cir. 2013); Bell v. [read post]
20 Mar 2009, 2:05 am
Sterling Drug, Inc., 416 F.2d 417, 426 (2d Cir. 1969).District of Columbia: McNeil Pharmaceutical v. [read post]
11 Jan 2010, 4:08 pm
Riyad; Eureka Water Co. v. [read post]
24 Jul 2008, 10:00 pm
District of Columbia, 747 A.2d 138145 (D.C. 2000); Mervin v. [read post]
19 Jun 2022, 5:08 am
District Court’s docket, represented nearly a quarter of the District’s entire civil docket. [read post]
18 May 2009, 5:24 am
: Omnicare, Inc v OHIM, Astellas Pharma GmbH (Class 46) CFI delivers judgment in case concerning ability of designer who assigns business and related IP to another company, to object when the company tries to register his name as a CTM: Elio Fiorucci v OHIM (IPKat) CFI: Good faith irrelevant when selling non-misleading sausages: Alberto Severi, in his own name and representing Cavazzuti e figli SpA, now known as Grandi Salumifici Italiani SpA v Regione… [read post]
28 Apr 2011, 3:18 pm
Thus “[w]e do not believe comment k was intended to provide nor should it provide all ethical drugs with blanket immunity from strict liability design defect claims. [read post]
18 Sep 2008, 8:56 pm
W. [read post]
9 Aug 2018, 2:37 pm
Harris Funeral Homes, Inc. v. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
18 Mar 2010, 2:47 pm
West Penn Power Co., 147 F.3d 256, 263 & n.13 (3d Cir. 1998) (“[w]e do draw on the allegations of the complaint, but in a realistic, rather than a slavish, manner”; rejecting “unsupported conclusions and unwarranted inferences”); Columbia Natural Resources, Inc. v. [read post]
13 Aug 2013, 9:30 am
The Court of Appeals for the District of Columbia Circuit agreed, finding that such boycotts were significantly expressive such that an ad hoc balancing of the competing interests presented in the particular case was necessary. [read post]
17 Oct 2021, 2:17 pm
Gladys Kessler, who sits on the District Court for the District of Columbia. [read post]
December 21, 2009 – Environmental Law Settlements, Decisions, Regulatory Actions and Lawsuit Filings
21 Dec 2009, 10:57 am
— Imelda V. [read post]
23 Dec 2009, 4:42 pm
— Imelda V. [read post]
